His primary areas of study are Virology, Virus, Flavivirus, Immunogenicity and Dengue virus. His Virology research is multidisciplinary, incorporating perspectives in Cytoplasm and Antibody, Immunology. His research in Virus intersects with topics in Immunoelectron microscopy, Endocytosis and Monocyte.
His research investigates the connection between Immunogenicity and topics such as Adjuvant that intersect with issues in Clinical trial, Adverse effect and Randomized controlled trial. His work on Antibody-dependent enhancement is typically connected to Recombinant virus as part of general Dengue virus study, connecting several disciplines of science. His Vaccination research incorporates themes from Viremia, Dengue vaccine and Reactogenicity.
Virology, Virus, Dengue fever, Dengue virus and Vaccination are his primary areas of study. His Virology study integrates concerns from other disciplines, such as Antibody, Immunology and Immunogenicity. His Virus research incorporates elements of Clone and Microbiology.
Kenneth H. Eckels has included themes like Microneutralization Assay, Viremia, Yellow fever and Serial passage in his Dengue fever study. His Dengue virus research includes elements of Attenuated vaccine, Virulence, Serotype and Vaccine efficacy. His study on Vaccination also encompasses disciplines like
His primary scientific interests are in Virology, Vaccination, Dengue virus, Immunogenicity and Dengue fever. His Virology study combines topics in areas such as Immunology and Immunity. His biological study focuses on Dengue vaccine.
His studies examine the connections between Immunogenicity and genetics, as well as such issues in Clinical trial, with regards to Randomized controlled trial. His Dengue fever research focuses on Microneutralization Assay and how it connects with Retrospective cohort study and Incidence. The Zika virus study combines topics in areas such as Viremia, Flavivirus and Immunization, DNA vaccination.
Kenneth H. Eckels focuses on Zika virus, Virology, Vaccination, Immunology and DNA vaccination. In his study, Clinical trial, Adverse effect, Randomized controlled trial and Internal medicine is strongly linked to Immunogenicity, which falls under the umbrella field of Zika virus. His biological study deals with issues like Neutralizing antibody, which deal with fields such as Dengue vaccine, Vaccination schedule, Dengue fever and Dengue virus.
His Immunology study focuses mostly on Antibody, Viral Vaccine and Flavivirus. He interconnects Viremia, Congenital disease and Outbreak in the investigation of issues within DNA vaccination. His Immunization study combines topics from a wide range of disciplines, such as Titer, Antibody titer, Virus and Immunity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Vaccine protection against Zika virus from Brazil
Rafael A. Larocca;Peter Abbink;Jean Pierre S. Peron;Paolo M. de A. Zanotto.
Nature (2016)
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
Peter Abbink;Rafael A. Larocca;Rafael A. De La Barrera;Christine A. Bricault.
Science (2016)
Rapid development of a DNA vaccine for Zika virus
Kimberly A. Dowd;Sung-Youl Ko;Kaitlyn M. Morabito;Eun Sung Yang.
Science (2016)
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Robert Edelman;Steven S. Wasserman;Sacared A. Bodison;Robert J. Putnak.
American Journal of Tropical Medicine and Hygiene (2003)
Monoclonal Antibodies Against Dengue 2 Virus E-Glycoprotein Protect Mice Against Lethal Dengue Infection,
B. M. Kaufman;P. L. Summers;D. R. Dubois;K. H. Eckels.
American Journal of Tropical Medicine and Hygiene (1987)
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
J. Robert Putnak;Beth-Ann Coller;Gerald Voss;David W. Vaughn.
Vaccine (2005)
Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection
B M Kaufman;P L Summers;D R Dubois;W H Cohen.
American Journal of Tropical Medicine and Hygiene (1989)
Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
Wellington Sun;Robert Edelman;Niranjan Kanesa-Thasan;Kenneth H. Eckels.
American Journal of Tropical Medicine and Hygiene (2003)
Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys
Robert Putnak;David A. Barvir;Jeanne M. Burrous;Doria R. Dubois.
The Journal of Infectious Diseases (1996)
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
Kayvon Modjarrad;Leyi Lin;Sarah L George;Sarah L George;Kathryn E Stephenson;Kathryn E Stephenson.
The Lancet (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
GlaxoSmithKline (United Kingdom)
Walter Reed Army Institute of Research
Bill & Melinda Gates Foundation
Beth Israel Deaconess Medical Center
Northwestern University
United States Department of the Army
Walter Reed Army Institute of Research
United States Department of the Army
Beth Israel Deaconess Medical Center
United States Department of the Army
Fraunhofer Institute for Intelligent Analysis and Information Systems
University of Technology Sydney
Southern Methodist University
University of Waterloo
Georgia Institute of Technology
Simon Fraser University
University of Tasmania
Florida Museum of Natural History
University of Mississippi
University of Nebraska Medical Center
National Institutes of Health
University of California, San Diego
University of Toronto
Ben-Gurion University of the Negev
Leibniz Institute for Neurobiology